Cellular Therapy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2021-03-25

AUTHORS

Nirav N. Shah , Adam Levin , Vivek S. Radhakrishnan , Parameswaran Hari

ABSTRACT

Cell-based immune therapies have been a mainstay for the management of patients with hematological malignancies. While historically allogeneic transplant and donor lymphocyte infusions were the predominant form of cell therapy utilized, recent developments in T cell-based treatments have significantly advanced the field. Specifically, the advent of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell therapies has provided a new powerful tool for patients with relapsed and refractory B cell malignancies. In this chapter, the development of CAR-T cell therapies will be reviewed along with its current and future applications and a detailed description of the potential toxicities associated with this novel treatment. In conclusion, CAR-T cells have revolutionized the field of hematological malignancies and high potential to alter the natural history of these diseases. More... »

PAGES

741-761

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-030-36358-1_3

DOI

http://dx.doi.org/10.1007/978-3-030-36358-1_3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1136640256


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Nirav N.", 
        "id": "sg:person.015270014615.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Levin", 
        "givenName": "Adam", 
        "id": "sg:person.014766516573.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014766516573.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Hematology Oncology and Hematopoietic Cell Transplantation, Tata Medical Center, Kolkata, India", 
          "id": "http://www.grid.ac/institutes/grid.430884.3", 
          "name": [
            "Clinical Hematology Oncology and Hematopoietic Cell Transplantation, Tata Medical Center, Kolkata, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radhakrishnan", 
        "givenName": "Vivek S.", 
        "id": "sg:person.015100736543.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015100736543.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology Oncology, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology Oncology, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hari", 
        "givenName": "Parameswaran", 
        "id": "sg:person.01170403141.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170403141.13"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-03-25", 
    "datePublishedReg": "2021-03-25", 
    "description": "Cell-based immune therapies have been a mainstay for the management of patients with hematological malignancies. While historically allogeneic transplant and donor lymphocyte infusions were the predominant form of cell therapy utilized, recent developments in T cell-based treatments have significantly advanced the field. Specifically, the advent of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell therapies has provided a new powerful tool for patients with relapsed and refractory B cell malignancies. In this chapter, the development of CAR-T cell therapies will be reviewed along with its current and future applications and a detailed description of the potential toxicities associated with this novel treatment. In conclusion, CAR-T cells have revolutionized the field of hematological malignancies and high potential to alter the natural history of these diseases.", 
    "editor": [
      {
        "familyName": "Chandy", 
        "givenName": "Mammen", 
        "type": "Person"
      }, 
      {
        "familyName": "Radhakrishnan", 
        "givenName": "Vivek S.", 
        "type": "Person"
      }, 
      {
        "familyName": "Sukumaran", 
        "givenName": "Reghu K.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-030-36358-1_3", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-030-36357-4", 
        "978-3-030-36358-1"
      ], 
      "name": "Contemporary Bone Marrow Transplantation", 
      "type": "Book"
    }, 
    "keywords": [
      "cell therapy", 
      "hematological malignancies", 
      "chimeric antigen receptor-modified T-cell therapy", 
      "cell-based immune therapy", 
      "T cell-based treatments", 
      "refractory B-cell malignancies", 
      "CAR T-cell therapy", 
      "donor lymphocyte infusion", 
      "management of patients", 
      "T-cell therapy", 
      "CAR T cells", 
      "B-cell malignancies", 
      "cell-based treatments", 
      "lymphocyte infusion", 
      "allogeneic transplants", 
      "immune therapy", 
      "cell malignancies", 
      "novel treatments", 
      "therapy", 
      "natural history", 
      "cellular therapy", 
      "malignancy", 
      "patients", 
      "treatment", 
      "potential toxicity", 
      "CD19", 
      "transplant", 
      "predominant form", 
      "infusion", 
      "mainstay", 
      "disease", 
      "toxicity", 
      "conclusion", 
      "cells", 
      "management", 
      "development", 
      "history", 
      "new powerful tool", 
      "advent", 
      "potential", 
      "recent developments", 
      "detailed description", 
      "powerful tool", 
      "tool", 
      "high potential", 
      "future applications", 
      "form", 
      "chapter", 
      "description", 
      "field", 
      "applications"
    ], 
    "name": "Cellular Therapy", 
    "pagination": "741-761", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1136640256"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-030-36358-1_3"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-030-36358-1_3", 
      "https://app.dimensions.ai/details/publication/pub.1136640256"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_214.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-030-36358-1_3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-36358-1_3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-36358-1_3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-36358-1_3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-36358-1_3'


 

This table displays all metadata directly associated to this object as RDF triples.

146 TRIPLES      22 PREDICATES      74 URIs      67 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-030-36358-1_3 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author N198f0a02c2c5488cb4b476b165824848
4 schema:datePublished 2021-03-25
5 schema:datePublishedReg 2021-03-25
6 schema:description Cell-based immune therapies have been a mainstay for the management of patients with hematological malignancies. While historically allogeneic transplant and donor lymphocyte infusions were the predominant form of cell therapy utilized, recent developments in T cell-based treatments have significantly advanced the field. Specifically, the advent of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell therapies has provided a new powerful tool for patients with relapsed and refractory B cell malignancies. In this chapter, the development of CAR-T cell therapies will be reviewed along with its current and future applications and a detailed description of the potential toxicities associated with this novel treatment. In conclusion, CAR-T cells have revolutionized the field of hematological malignancies and high potential to alter the natural history of these diseases.
7 schema:editor Nd4afb0aa4e6a4d039cababd7dce59ed1
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nc0b5932d519f4150b1137cd3ff1aec3e
11 schema:keywords B-cell malignancies
12 CAR T cells
13 CAR T-cell therapy
14 CD19
15 T cell-based treatments
16 T-cell therapy
17 advent
18 allogeneic transplants
19 applications
20 cell malignancies
21 cell therapy
22 cell-based immune therapy
23 cell-based treatments
24 cells
25 cellular therapy
26 chapter
27 chimeric antigen receptor-modified T-cell therapy
28 conclusion
29 description
30 detailed description
31 development
32 disease
33 donor lymphocyte infusion
34 field
35 form
36 future applications
37 hematological malignancies
38 high potential
39 history
40 immune therapy
41 infusion
42 lymphocyte infusion
43 mainstay
44 malignancy
45 management
46 management of patients
47 natural history
48 new powerful tool
49 novel treatments
50 patients
51 potential
52 potential toxicity
53 powerful tool
54 predominant form
55 recent developments
56 refractory B-cell malignancies
57 therapy
58 tool
59 toxicity
60 transplant
61 treatment
62 schema:name Cellular Therapy
63 schema:pagination 741-761
64 schema:productId N3725cc922441450cb7242dda87bf0b17
65 Nc605898fd0d7478ebda1bcde4949ac58
66 schema:publisher N30f04f7288b44f03968dd207d74254e6
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136640256
68 https://doi.org/10.1007/978-3-030-36358-1_3
69 schema:sdDatePublished 2022-09-02T16:12
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher Na16659d39c274d5890e54279c1053c5e
72 schema:url https://doi.org/10.1007/978-3-030-36358-1_3
73 sgo:license sg:explorer/license/
74 sgo:sdDataset chapters
75 rdf:type schema:Chapter
76 N0252450e6c544634bdaa964d47076dda schema:familyName Radhakrishnan
77 schema:givenName Vivek S.
78 rdf:type schema:Person
79 N198f0a02c2c5488cb4b476b165824848 rdf:first sg:person.015270014615.39
80 rdf:rest Na2837afc326d4783aa6644eddfe92750
81 N1b4c5824a57f4d64b266c4fbd0145751 rdf:first Nf09289b2f23649828bafbaa38bbff7d0
82 rdf:rest rdf:nil
83 N1cb2a014fd4b4877954f9d500b73cab6 rdf:first N0252450e6c544634bdaa964d47076dda
84 rdf:rest N1b4c5824a57f4d64b266c4fbd0145751
85 N30f04f7288b44f03968dd207d74254e6 schema:name Springer Nature
86 rdf:type schema:Organisation
87 N3725cc922441450cb7242dda87bf0b17 schema:name doi
88 schema:value 10.1007/978-3-030-36358-1_3
89 rdf:type schema:PropertyValue
90 Na16659d39c274d5890e54279c1053c5e schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 Na2837afc326d4783aa6644eddfe92750 rdf:first sg:person.014766516573.70
93 rdf:rest Nc7e2c1d29a6140abbf1fc647badada34
94 Nb3365ef69f6b4695973167860ae88036 schema:familyName Chandy
95 schema:givenName Mammen
96 rdf:type schema:Person
97 Nc0b5932d519f4150b1137cd3ff1aec3e schema:isbn 978-3-030-36357-4
98 978-3-030-36358-1
99 schema:name Contemporary Bone Marrow Transplantation
100 rdf:type schema:Book
101 Nc605898fd0d7478ebda1bcde4949ac58 schema:name dimensions_id
102 schema:value pub.1136640256
103 rdf:type schema:PropertyValue
104 Nc7e2c1d29a6140abbf1fc647badada34 rdf:first sg:person.015100736543.25
105 rdf:rest Ncd6de3dbda4248039150a80803411e79
106 Ncd6de3dbda4248039150a80803411e79 rdf:first sg:person.01170403141.13
107 rdf:rest rdf:nil
108 Nd4afb0aa4e6a4d039cababd7dce59ed1 rdf:first Nb3365ef69f6b4695973167860ae88036
109 rdf:rest N1cb2a014fd4b4877954f9d500b73cab6
110 Nf09289b2f23649828bafbaa38bbff7d0 schema:familyName Sukumaran
111 schema:givenName Reghu K.
112 rdf:type schema:Person
113 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
114 schema:name Medical and Health Sciences
115 rdf:type schema:DefinedTerm
116 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
117 schema:name Immunology
118 rdf:type schema:DefinedTerm
119 sg:person.01170403141.13 schema:affiliation grid-institutes:grid.30760.32
120 schema:familyName Hari
121 schema:givenName Parameswaran
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170403141.13
123 rdf:type schema:Person
124 sg:person.014766516573.70 schema:affiliation grid-institutes:grid.30760.32
125 schema:familyName Levin
126 schema:givenName Adam
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014766516573.70
128 rdf:type schema:Person
129 sg:person.015100736543.25 schema:affiliation grid-institutes:grid.430884.3
130 schema:familyName Radhakrishnan
131 schema:givenName Vivek S.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015100736543.25
133 rdf:type schema:Person
134 sg:person.015270014615.39 schema:affiliation grid-institutes:grid.30760.32
135 schema:familyName Shah
136 schema:givenName Nirav N.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39
138 rdf:type schema:Person
139 grid-institutes:grid.30760.32 schema:alternateName Division of Hematology Oncology, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA
140 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
141 schema:name Division of Hematology Oncology, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA
142 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
143 rdf:type schema:Organization
144 grid-institutes:grid.430884.3 schema:alternateName Clinical Hematology Oncology and Hematopoietic Cell Transplantation, Tata Medical Center, Kolkata, India
145 schema:name Clinical Hematology Oncology and Hematopoietic Cell Transplantation, Tata Medical Center, Kolkata, India
146 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...